ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CRDA Croda International Plc

4,220.00
-80.00 (-1.86%)
07 Oct 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Croda International Plc LSE:CRDA London Ordinary Share GB00BJFFLV09 ORD 10.609756P
  Price Change % Change Share Price Shares Traded Last Trade
  -80.00 -1.86% 4,220.00 443,603 16:35:21
Bid Price Offer Price High Price Low Price Open Price
4,227.00 4,232.00 4,317.00 4,228.00 4,316.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Chemicals & Chem Preps, Nec 1.69B 171M 1.2246 34.53 6B
Last Trade Time Trade Type Trade Size Trade Price Currency
16:39:32 AT 342 4,220.00 GBX

Croda (CRDA) Latest News

Croda (CRDA) Discussions and Chat

Croda Forums and Chat

Date Time Title Posts
27/9/202414:34CRODA331
24/7/201822:20Croda Intl (CRDA) One to Watch on Wednesday -
23/7/201415:31TipTv analyses the prospects of Croda International PLC (CRDA)-
25/7/201220:28CRODA BACK TO Ј7253
05/2/200714:35Strong Outlook98

Add a New Thread

Croda (CRDA) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:39:324,220.0034214,432.40AT
15:35:214,220.00237,72410,031,952.80UT
15:29:594,229.0029412,433.26O
15:29:594,228.00943,974.32AT
15:29:594,229.0012507.48AT

Croda (CRDA) Top Chat Posts

Top Posts
Posted at 07/10/2024 09:20 by Croda Daily Update
Croda International Plc is listed in the Chemicals & Chem Preps, Nec sector of the London Stock Exchange with ticker CRDA. The last closing price for Croda was 4,300p.
Croda currently has 139,635,442 shares in issue. The market capitalisation of Croda is £5,903,786,488.
Croda has a price to earnings ratio (PE ratio) of 34.53.
This morning CRDA shares opened at 4,316p
Posted at 12/7/2024 21:42 by wad collector
Yes that concept can only be used for a finite period. But ultimately they are in a reasonable niche with multiple products, they will prosper again eventually if they maintain market share.
They are still double what they were a decade ago. Unimpressive but steady, if we ignore the covid bonus.

free stock charts from uk.advfn.com
Posted at 03/7/2024 17:43 by uhound
Depends on how the market values the company.

Based on earnings and assets £30 per share?

EPS has declined a lot over the last few years, but perhaps we may se a recovery this year?
Posted at 01/7/2024 09:22 by scobak
I look at the price and the fundamentals.
Currently £39.20 and falling.
Historically £39.52 is a good price but perhaps not a really good entry point.
Posted at 29/6/2024 10:56 by stoopid
Bought in at 3952. With the RSI below 30 and the lowest share price in around 5 years I hope it's a good entry point....
Posted at 28/6/2024 11:00 by stoopid
But only for an hour or so and has already bounces back above.Been watching CRDA foe a while now and wondering if now is the right time to buy in?
Posted at 27/2/2024 07:49 by battyliveson
Poor numbers, but probably expected given share price movements in last couple of years.

I think a fair value for croda is around £4.4 to £5.6bn, so will wait before I get back in.

B
Posted at 05/2/2024 16:38 by wad collector
Bouncing off £50 atm , maybe the worse is behind CRDA now, this is an industry with high barriers to entry , but still a long way back to the heady £100 days of 2021.
Posted at 14/12/2023 14:02 by smcni1968
Croda a long C-road to recoveryOperationally, a load C-road to recovery. We reduce Croda estimates c. 12% for FY24 and our target price to £53. In Consumer Care, we expect a sequential improvement in destocking; however, as demonstrated above, the overhang of inventories at HPC customers remains into the start of FY24. With a realignment of customer inventories globally still ongoing (esp. in Asia) and slower growth from large-cap customers more generally, the snap-back will not be immediate. This has raised and continues to raise debate around the defensiveness and quality of Croda's Consumer Care portfolio, given volume declines well in excess of even its lowest-quality peers, despite the cushioning from substantial growth in Iberchem.From an earnings perspective, even with stabilising volumes y/y, earnings remain impacted by operating deleverage and high-priced inventories. With it clear Ag end markets are unlikely to recover until H2. While volumes seem to be turning (Actives up y/y, Beauty Effects still negative) and despite work on inventories, we are not completely out of the woods, with inventories still above average. Risk therefore remains that the boost in volumes through September/October is short-lived near term, and thus, the outlook remains weak. We expect a weak 1H24 - essentially reflecting the 2H run rates, with a more meaningful improvement coming through as the year progresses.Strategically, poised but not yet able to catalyse growth given operational challenges. In the mid-term, Croda's less levered balance sheet than peers provides optionality from an acquisition perspective, with ND/EBITDA still c1x (at current EBITDA levels c1.4x). In the near term, the ability to acquire businesses remains constrained, with the attractive IFF Lucas Meyer assets too expensive, given current uncertainties in outlook and in managing the core business. Overall, that high-multiple stocks can get these deals executed at these multiples is another affirmation that multiples in the sector remain too high. For Croda to participate further in acquisitions, we believe a meaningful decline in industry multiples must be evident in asset prices.
Posted at 19/9/2023 16:27 by commuter10
This gives real cause for concern as share price has now halved from Mid-2021 levels.

Is this a hold or sell share now do we think?
Posted at 15/6/2023 21:55 by steeplejack
Berenberg cut its price target on Croda as it trimmed estimates a week after the specialty chemicals firm warned on profits, but maintained its 'buy' recommendation.

The bank, which reduced the price target to £66 from £80 ,said big profit warnings from Croda are rare - as are good entry points.
“The last time the company issued a trading update remotely as bearish as the one of 9 June 2023 was on 24 June 2014, when industrials were a larger part of mix," it noted.
“The smooth journey for Croda over the difficult subsequent period for the chemicals sector - one of Chinese overcapacity, then the Covid-19 pandemic, then the European energy crisis - speaks for the robustness of the business.

"The recovery of shares,following the 2014 warning, suggests it is a good idea to buy on weakness. We understand that US order books show some signs of improvement, and survey data (see our consumer team's China review) point to a solid outlook for China.

"Europe is not yet at the end of squeeze on discretionary incomes, but volumes should improve by the start of FY24."

Berenberg said the 20% cuts to its earnings per share estimates reflect lower sales volumes and prices in consumer care and crop protection, in addition to lower prices for by-product sales in the industrial specialities segment.
Croda share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock